AnaptysBio

Clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. $ANAB

[AnaptysBio @AnaptysBio]

We’ve announced a $100 million equity offering, led by long-standing investor EcoR1 Capital, LLC, with participation from additional existing and new investors, including Sanofi.

The offering is expected to close ~Aug. 15, 2024, subject to customary closing conditions.

$ANAB

[AnaptysBio @AnaptysBio]

Today, we announced our #Q2 earnings and provided an update on our work to develop immune cell modulators for patients living with #Autoimmune and #InflammatoryDiseases.

Read our full announcement: https://t.co/OFTWpEl0Sa

#Q2Earnings $ANAB

[AnaptysBio @AnaptysBio]

Yesterday, we announced a $50 million capped non-recourse monetization with Sagard in exchange for additional Jemperli royalties. Proceeds from this transaction will further enable development of our best-in-class #ImmuneCellModulator portfolio: https://t.co/YP70Afd0eC

$ANAB

[AnaptysBio @AnaptysBio]

Today, we announced our #Q1 update. Catch up on our progress developing best-in-class immune cell modulators (ICMs) for patients living with heterogeneous, systemic autoimmune and inflammatory diseases.

Learn more: https://t.co/ycI4J21gKc

#Q1Earnings $ANAB

[AnaptysBio @AnaptysBio]

Season’s greetings from Anaptys!

Wishing you a joyous, peaceful holiday season. May 2024 bring new discoveries, breakthroughs, and continued progress toward a healthier future for all.

#WeAreAnaptysBio

[AnaptysBio @AnaptysBio]

From initiating #ClinicalTrials in multiple therapeutic areas to adding amazing new team members, we made significant progress in 2023. Learn about a few key milestones below.

#WeAreAnaptysBio

[AnaptysBio @AnaptysBio]

We believe the PD-1 pathway may play a key role in the treatment of #UlcerativeColitis. Learn more here: https://t.co/Kw3lrkxa4n
#CCAwarenessWeek

[AnaptysBio @AnaptysBio]

Thank you, @CrohnsColitisFn, for joining us virtually during #CCAwarenessWeek and sharing how we can work together to better support the #IBD community.

#WeAreAnaptysBio

[AnaptysBio @AnaptysBio]

In honor of #CCAwarenessWeek, we encourage followers to check out the following UC resources:

https://t.co/rdSXBt1TSL
https://t.co/AzHVqhsLtY

[AnaptysBio @AnaptysBio]

If you are living with #UlcerativeColitis, you know how challenging this #InflammatoryDisease can be. We’re committed to sharing resources for the journey.

[AnaptysBio @AnaptysBio]

Today, we’re spotlighting Tae Lee, an exceptional colleague who embodies our company’s core values and plays a key role in our ongoing work to deliver innovative immunology therapeutics.

We’re so glad you’re on our team, Tae!

[AnaptysBio @AnaptysBio]

#NEWS: Today, we announced an exclusive license agreement for @Centessa’s blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio for the treatment of autoimmune and inflammatory diseases. Learn more: https://t.co/boshAnhkBZ

[AnaptysBio @AnaptysBio]

We have recently welcomed six exceptional new colleagues to the Anaptys team. Learn about their roles below.

#WeAreAnaptysBio

[AnaptysBio @AnaptysBio]

Great connecting with friends old and new at #ACR23. While there’s still plenty of work ahead to address the needs of people living with #Rheumatic diseases, we’re inspired by the progress made to date.

[American College of Rheumatology @ACRheum]

Highlights from #ACR23—where #rheum meets!

[AnaptysBio @AnaptysBio]

#ICYMI: Last month, we hosted a virtual R&D event to discuss important updates on our PD-1 Agonist #MoncolonalAntibody for #RheumatoidArthritis and #UlcerativeColitis. Listen to the full recording: https://t.co/B9Qm3b5315

$ANAB

[AnaptysBio @AnaptysBio]

#ACR23 attendees: don’t miss your chance to learn about our ongoing research and work to support people living with #InflammatoryDisease, including RA. Visit our posters in the Poster Hall today through Tuesday.

[American College of Rheumatology @ACRheum]

And we’re back! The #ACR23 Poster Hall is officially open for business, 8:30 AM to 4:00 PM PT, Sunday through Tuesday. 👏👏👏

[AnaptysBio @AnaptysBio]

Hello, #ACR23! We’re thrilled to be in our hometown of San Diego for six full days of learning and meaningful engagement with fellow leaders in #Rheumatology and #LifeSciences. Conference attendees, learn about our poster presentations below. @ACRheum

[AnaptysBio @AnaptysBio]

An estimated four in 10 people living with #RheumatoidArthritis (RA) do not achieve disease remission with current standard of care. Dr. Jonathan Graf of @UCSFRheum offers his perspective on the unmet needs in the community.

[AnaptysBio @AnaptysBio]

#NEWS: We are thrilled to share that @Biospace has named AnaptysBio a Best Place to Work for 2024! This recognition is a tremendous honor and testament to all the incredible team members who shape our one-of-a-kind #companyculture.

Learn more: https://t.co/9zn0j3erYd

[AnaptysBio @AnaptysBio]

We’re developing a best-in-class portfolio of immune cell modulators to help dampen the inflammatory response and restore immune balance. Anaptys president and CEO Daniel Faga reflects on pipeline progress.

#Q3Earnings $ANAB

https://t.co/KXD7tSiPeR